tirzepatide chronic kidney disease trial SURPASS-4: Tirzepatide slows kidney disease in adults with type 2 diabetes, CV risk

New Cleveland Clinic research finds tirzepatide is associated with a 16% lower risk of major heart and kidney complications compared with dulaglutide in people with Type 2 diabetes and heart disease. The

21.86

★★★★☆4.8 (126)

Tirzepatide Shows Kidney Benefits in T2D: SURPASS Trials Analysis

25.72

★★★★★4.9 (98)

At #ACC25, Dr. Milton Packer and colleagues present a new secondary analysis from the SUMMIT trial evaluating the effect of tirzepatide in patients with obesity, #HFpEF, and CKD. The trial demonstrated that #

29.85

★★★★★5.0 (157)

CONFIDENCE trial: In persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone

22.04

★★★★★4.7 (84)

Tirzepatide Demonstrates Remarkable Kidney Protection in Type 2 Diabetes Patients Compared to Dulaglutide

20.07

★★★★★4.9 (203)

Tirzepatide (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https

22.05

★★★★★5.0 (176)

An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

25.10

★★★★★4.8 (132)